3 ms·
I’m not surprised that every egregious example of spreads is for recently launched generic drugs. The key problem with drug reimbursement is knowing what price
by refurb 8y ago
I’m not surprised that every egregious example of spreads is for recently launched generic drugs.
The key problem with drug reimbursement is knowing what price the pharmacy paid. Drug manufacturers have list prices, but offer discounts and rebates to drop the price, particularly when a drug goes generic.
So if the list price is $100, the pharmacy might have paid anywhere from $95 to $5 for the drug.
In the past the PBMs are correct, that spread went to the pharmacies. That’s less of a bug and more of a feature - it incentivized the use of generic drugs.
Basically the PBMs inserted themselves in the process and grabbed the spread for themselves.
- shimon 8y agoThis is a good point. Newly launched generic drugs go through a period of rapid price adjustment, where at first they are priced only a little bit below the brand-name drug. Then as more generics become available (and keep in mind we're talking about physical products with expiration dates, inventory and distribution delays, etc.) the best wholesale price drops. In theory this is an area where PBMs can add a lot of value, because they have broader visibility into the pricing of these drugs (both by researching manuf pricing and negotiating prices with pharmacies).
- briffle 8y agoThe other thing this article fails to mention, is that while a new generic was billed at $100, and the pharmacy got $20 (with an $80 spread) before there was a generic, the prescription was billed in the thousands. The person paying the bill is still paying less, and overall, the company should see its bills go down.